Biotech News

Fresenius Medical Care places bonds with a volume of 1.1 billion euros

freseniusmedicalcare.com2026-05-06 14:44 EST

The information and documents contained on the following pages of this website are for information purposes only. These materials do not constitute either an offer or an invitation to subscribe to or to purchase any securities, or any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. All of the securities described in these materials have been issued and sold by the Company. Such securities have not been and will not be registered under the US Securities Act of 1933, as amended (the “Securities Act”) and may not be reoffered or resold in the US or to any “US persons” as defined in Regulation S under the Securities Act, absent registration under the Securities Act or an exemption from registration.

THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, OR WHO ARE “US PERSONS” (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT) OTHER THAN “QUALIFIED INSTITUTIONAL BUYERS” (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT), (II) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN CANADA, JAPAN OR AUSTRALIA, OR (III) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.

To visit the following parts of this website you must confirm that

(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act), except as permitted by (ii), below,

(ii) if you are a resident of the United States of America or a US person, you are a “qualified institutional buyer” (as defined in Rule 144A under the US Securities Act),

(iii) you are not otherwise a person to whom the communication of the information contained on this website is restricted,

(iv) you will not distribute any of the information and documents contained thereon to any such person, and

(v) you are not acting for the benefit of any person described in clauses (i), (ii) or (iii) above.

By clicking on the "Accept" button below, you will be deemed to have made this confirmation

Fresenius Medical Care places bonds with a volume of 1.1 billion euros

04/01/2025 | Press Release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN.

<ul>

<li>€600 million maturing in December 2028 and a coupon of 3.125% p.a. were issued at a price of 99.558% resulting in a yield of 3.258%.</li>

<li>€500 million maturing in April 2032 and a coupon of 3.750% p.a. were issued at a price of 99.372% resulting in a yield of 3.854%.</li>

</ul>

<li>€600 million maturing in December 2028 and a coupon of 3.125% p.a. were issued at a price of 99.558% resulting in a yield of 3.258%.</li>

<li>€500 million maturing in April 2032 and a coupon of 3.750% p.a. were issued at a price of 99.372% resulting in a yield of 3.854%.</li>

The proceeds will be used for general corporate purposes, including the refinancing of existing financial liabilities.

The bonds were drawn under the Debt Issuance Program (DIP) by Fresenius Medical Care. The company has applied to the Luxembourg Stock Exchange to admit the bonds to trading on its regulated market.

The envisaged settlement date is April 8, 2025.

About Fresenius Medical Care: Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,675 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

Disclaimer: This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in Australia, Canada, Japan, or the United States of America (the “United States”) or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent such registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to herein has not been and will not be registered under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.

This announcement has been prepared on the basis that any offer of bonds in any Member State of the European Economic Area (each, a Member State) will only be made (i) pursuant to a prospectus prepared by Fresenius Medical Care AG pursuant to Regulation (EU) 1129/2017 (as amended, the “Prospectus Regulation”), as supplemented, or (ii) pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of securities. Fresenius Medical Care has not authorized, nor does it authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius Medical Care or any other person to publish or supplement a prospectus for such offer.

This announcement is directed at and/or for distribution only to persons who (i) are outside the United Kingdom; (ii) who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), (iii) are high net worth entities falling within article 49(2)(a) to (d) of the Order; or (iv) other persons to whom it may otherwise be lawfully communicated (all such persons together being referred to as “relevant persons”). This announcement is directed only at relevant persons. Any person who is not a relevant person should not act or rely on this announcement or any of its contents. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

This announcement has been prepared on the basis that any offer of bonds in the United Kingdom will only be made pursuant to an exemption under Section 86 of the Financial Services and Markets Act 2000 from the requirement to publish a prospectus for offers of securities. Fresenius Medical Care has not authorized, nor does it authorize, the making of any offer of securities in circumstances in which an obligation arises for Fresenius Medical Care or any other person to publish or supplement a prospectus for such offer.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Back

To top:

Full article